Crossmark

A Japanese registry for optimizing the safe use of anti-amyloid therapies for Alzheimer’s disease in Japan

Crossref DOI link: https://doi.org/10.1038/s43587-025-00980-5

Published Online: 2025-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iwatsubo, Takeshi https://orcid.org/0000-0003-1160-8129
License Information

Text and Data Mining valid from 2025-09-26

Version of Record valid from 2025-09-26
More Information

Article History

First Online: 26 September 2025

Competing interests

: The author has received consultancy and/or speakers fees from Eisai, Eli-Lilly and Company, Fujirebio and Fujifilm.